GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript

Boris Peaker: Great. Thanks for taking my question. First, can you remind us — maybe I missed that, how many patients in the upro study went on to transplant and also what the dropout rate was.

Harout Semerjian: Good morning, Boris. In which study?

Boris Peaker: In your study specifically. But I guess if you know them for the NCI study as well, I guess it would be helpful for both of them.

Harout Semerjian: Yes. What we have announced, Boris, as you know, is that in our Phase I trial in relapsed/refractory, we had seen a 31% transplant rate. And as mentioned before, in our Phase III, we are seeing a number north of that number. We have not disclosed the exact number. What we are saying is it’s north of 31%.

Boris Peaker: Got you. And the dropout rate?

Harout Semerjian: Ed?

Edwin Rock: Yes. The dropout rate is 3%.

Boris Peaker: Got you. Pretty low. I guess my last question is.

Harout Semerjian: It’s a very low number, yes.

Boris Peaker: My last question is on the NCI study. Do you have a sense of why that’s taking so long?

Harout Semerjian: Yes. I mean we have our opinions, obviously, but we have to wait for the data to see what’s happening. And as you know, the last patient enrolled in that trial in the Phase II population 267 patients was enrolled in December 2021. And that is an EFS primary endpoint for the Phase II. So we are very intrigued and hopeful that, that’s happening because events are not reaching. And if that’s the case, then that’s good news to patients, obviously. So we’ll see once they reach the events, we are — we collaborate with the NCI. We continue to have dialogues with them. And they have told us that when they get to the events, they will let us know. And until now, they have not done so.

Boris Peaker: Great. Thanks for taking my questions.

Harout Semerjian: Thank you, Boris.

Operator: And I’m showing no further questions at this time. I would now like to turn the call back to Harout for closing remarks.

Harout Semerjian: Thank you, operator, and thank you to everyone for joining our call today. We look forward to keeping you up-to-date on GlycoMimetics and seeing some of you at the Jefferies London Healthcare Conference or at ASH in December. Thank you very much.

Operator: Ladies and gentlemen, this concludes today’s conference. Thank you for your participation. You may now disconnect.